David A. Siegel Pmv Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q4 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Pmv Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 714,600 shares of PMVP stock, worth $993,293. This represents 0.0% of its overall portfolio holdings.

Number of Shares

714,600

Previous 751,200 4.87%

Holding current value

$993,293

Previous $1.12 Million 3.57%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$1.47 - $1.78 $53,802 - $65,148	-36,600 Reduced 4.87%	714,600 $1.08 Million
Q3 2024 Nov 14, 2024	BUY	$1.44 - $1.69 $371,088 - $435,513	257,700 Added 52.22%	751,200 $1.12 Million
Q2 2024 Aug 14, 2024	BUY	$1.51 - $2.21 $193,431 - $283,101	128,100 Added 35.06%	493,500 $799,000
Q1 2024 May 15, 2024	BUY	$1.51 - $3.12 $266,968 - $551,616	176,800 Added 93.74%	365,400 $621,000
Q4 2023 Feb 14, 2024	BUY	$1.23 - $6.6 $184,254 - $988,680	149,800 Added 386.08%	188,600 $584,000
Q3 2023 Nov 14, 2023	SELL	$6.01 - $8.93 $384,039 - $570,627	-63,900 Reduced 62.22%	38,800 $238,000
Q2 2023 Aug 14, 2023	BUY	$3.94 - $6.27 $188,332 - $299,706	47,800 Added 87.07%	102,700 $642,000
Q1 2023 May 15, 2023	BUY	$4.77 - $9.16 $261,872 - $502,884	54,900 New	54,900 $261,000
Q2 2022 Aug 15, 2022	SELL	$9.23 - $22.43 $259,363 - $630,283	-28,100 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$14.86 - $23.55 $95,104 - $150,720	-6,400 Reduced 18.55%	28,100 $585,000
Q4 2021 Feb 14, 2022	BUY	$19.99 - $30.24 $689,655 - $1.04 Million	34,500 New	34,500 $797,000

Others Institutions Holding PMVP

# of Institutions

Shares Held

43.2M

Call Options Held

3.1K

Put Options Held

1.7K

View Full List

About PMV Pharmaceuticals, Inc.

Ticker PMVP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,622,600
Market Cap $63.4M
Description
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...

More about PMVP

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account